Amplifai Health has successfully closed a new funding round, securing strategic investments from Wa’ed by Aramco, Plug and Play, and KAUST Innovation Ventures, alongside existing investors Techstars and Lamarka.
This funding will be instrumental in driving the company’s execution on its recently secured Saudi Food and Drug Authority (SFDA) approval for Thermal Foot Scan (TFscan), the world’s first Software as a Medical Device (SaMD) for diabetic foot screening.
Diabetic foot ulcers (DFUs) are a leading cause of lower-limb amputations, with diabetes-related amputations occurring every 20 seconds worldwide. Amplifai Health’s AI-powered TFscan technology provides clinicians with an innovative, non-invasive, and real-time thermal imaging solution to detect early signs of DFUs before they progress to severe complications.
Dr. Meshari Alwashmi, CEO of Amplifai Health said, “This funding is a significant milestone for Amplifai Health as we bring our SFDA-approved solution to clinicians and patients across Saudi Arabia and beyond.
“The investment will accelerate our execution, enabling us to scale operations, enhance product capabilities, and expand accessibility to TFscan.”
He added, “We are committed to transforming diabetic care, reducing amputations, and improving patient outcomes globally.”
With over 800 million people worldwide living with diabetes, a number expected to surpass 1 billion by 2030, the global burden of diabetes-related complications continues to grow. Saudi Arabia faces a particularly urgent need for proactive healthcare solutions, with 18.7% of adults living with diabetes.
Traditional diabetic foot screening methods rely on subjective visual assessment of patient-reported symptoms, often missing early-stage complications. TFscan leverages advanced thermal imaging and AI-driven analysis to provide clinicians with a detailed risk assessment, allowing for earlier and more effective intervention.
By reducing the incidence of DFUs and amputations, TFscan is poised to significantly lower healthcare costs, improve patient quality of life, and minimize the long-term burden of diabetes-related disabilities.
